Intraperitoneal Insulin: An Alternative Route When Traditional Injections Fall Short

Intraperitoneal insulin infusion is a method of delivering insulin directly into the peritoneal cavity—the space in the abdomen surrounding the internal organs—rather than under the skin. The insulin reaches the bloodstream through the peritoneal membrane, which lines this cavity. This route mimics how the pancreas naturally delivers insulin into the body and may offer metabolic advantages over traditional subcutaneous injection.

Despite major advances in continuous glucose monitoring, insulin pumps, and automated insulin delivery systems, some people with Type 1 diabetes face barriers that prevent them from achieving good control with standard subcutaneous insulin therapy.

These barriers include lipoatrophy (loss of fat tissue), lipodystrophy (abnormal fat distribution), or lipohypertrophy (thickened fat deposits) caused by repeated injections at the same sites; local allergic reactions to insulin or infusion sets; subcutaneous insulin resistance; and skin conditions that make injection-site care difficult. Others experience recurrent or unexplained severe hypoglycemic episodes or hyperglycemic swings despite optimized intensive therapy.

According to a comprehensive literature review and international position statement published in Diabetes, Obesity & Metabolism, intraperitoneal insulin delivery achieves glucose control that is comparable to or better than continuous subcutaneous insulin infusion. A key finding is that this route may reduce the frequency of hypoglycemic episodes, including severe lows—a meaningful benefit for people living with the constant threat of dangerous blood sugar drops.

The evidence base supports considering this approach for children and adults with Type 1 diabetes in specific clinical contexts, though the statement emphasizes that intraperitoneal insulin is not a first-line therapy.

Candidates for intraperitoneal insulin infusion include people with Type 1 diabetes who have optimized all other intensive insulin regimens and who meet specific criteria: skin damage from repeated injections, severe needle phobia, resistance to subcutaneous insulin, or persistent unexplained blood sugar dyscontrol. The approach is also relevant for people being evaluated for islet cell or pancreatic transplantation, or in settings where transplantation is not available.

This position statement is intended to guide diabetes specialist healthcare professionals in identifying candidates and understanding the potential benefits and risks of this delivery method. As with any treatment option, decisions should be made in partnership with your healthcare team based on your individual circumstances, and the goal remains the same: achieving stable blood sugar without dangerous lows or highs.

Source: Diabetes, obesity & metabolism. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.